Overview
This educational protocol combines two well-studied regenerative peptides: BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from human gastric juice with cytoprotective and wound-healing properties, and TB-500 (Thymosin Beta-4 fragment), a 43-amino acid peptide involved in tissue repair, cell migration, and angiogenesis.
Blend Composition
– BPC-157: 5 mg per vial
– TB-500: 5 mg per vial
– Total: 10 mg blend (1:1 ratio)
– Ratio: Each dose delivers equal amounts of both peptides
Reconstitution
Standard Method:
– Add 3.0 mL of bacteriostatic water to the 10 mg vial
– Resulting concentration: ~3.33 mg/mL (1.67 mg/mL of each peptide)
– On a U-100 insulin syringe: 1 unit = 0.01 mL ≈ 33.3 mcg of total blend
Handling:
– Allow the vial to reach room temperature before opening to reduce condensation
– Use sterile technique
– Mix gently; do not shake vigorously
Dosage Protocols
Standard/Gradual Approach (Beginners)
| Phase/Week | Total Daily Dose | Per Peptide | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg each | 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg each | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg each | 18 units (0.18 mL) |
Aggressive Approach (Acute Injury)
For acute tissue injuries, some protocols suggest a higher initial loading phase:
| Phase/Week | Total Daily Dose | Per Peptide | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1,000 mcg | 500 mcg each | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg each | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg each | 18 units (0.18 mL) |
Administration Frequency
– Route: Subcutaneous injection
– Frequency: Once daily
– Duration: 8–12 weeks; optional extension to 16 weeks
– Site rotation: Abdomen, thighs, upper arms, flank (at least 2 inches from the navel)
Storage
Lyophilized Form:
– Freeze at −20°C (−4°F) in dry, dark conditions
– Minimize moisture exposure
– Keep in sealed vial
After Reconstitution:
– Refrigerate between 2–8°C (35.6–46.4°F)
– Use within 4–6 weeks
– Avoid freeze-thaw cycles
– Keep refrigerated away from light
– Do not refreeze after thawing
How It Works
BPC-157
A stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects in gastrointestinal, musculoskeletal, and neurological tissues in pre-clinical models. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies.
TB-500 (Thymosin Beta-4)
An actin-sequestering peptide that promotes cell migration, wound healing, and anti-inflammatory responses. Well tolerated in animal and early clinical studies, even at multi-milligram doses.
Synergy
Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 through its trophic and anti-inflammatory effects, and TB-500 through enhanced cell migration and angiogenesis.
Potential Benefits
– May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries
– Pre-clinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157
– TB-500 promotes wound healing and may reduce scarring through enhanced cell migration
– Both peptides are generally well tolerated at studied doses
Side Effects and Safety
– Local reactions: Mild injection site irritation (redness, itching) may occur with subcutaneous administration
– Safety profile: No significant toxicity has been documented up to high doses in animal studies
– General tolerance: Both peptides are considered well tolerated in established protocols
Subcutaneous Injection Technique
– Clean vial stopper and skin with alcohol swabs; allow to dry completely
– Pinch a skin fold; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate; inject slowly and steadily
– Systematically rotate sites to prevent lipohypertrophy
– Apply gentle pressure post-injection; do not rub the site
Important Considerations
– Use new sterile insulin syringes for each injection; dispose in a sharps container
– Document daily dose and site rotation to maintain consistency
– Inject slowly; wait a few seconds before withdrawing the needle
Supply Planning
For an 8–16 week protocol with phased dosing (~700 mcg/day average):
| Resource | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide vials | 4 | 6 | 8 |
| Insulin syringes (U-100) | 56 | 84 | 112 |
| Bacteriostatic water (mL) | 12 mL | 18 mL | 24 mL |
| Alcohol swabs | 112 | 168 | 224 |
Lifestyle Factors
– Prioritize adequate protein intake (1.6–2.2 g/kg body weight) to support tissue repair
– Follow appropriate rehabilitation protocols for any injury being addressed
– Ensure adequate sleep (7–9 hours) to optimize recovery and tissue regeneration
– Manage inflammation through balanced nutrition and stress reduction techniques
Disclaimer
This content is for educational purposes only and does not constitute medical advice. These substances are not approved for routine human use. Always consult a qualified healthcare professional before initiating any research protocol.